SEASTAR MEDICAL HOLDING CORP (ICU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.98+2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ICU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -54.6% |
| Our one-year growth estimate | diamond | 52.7% |
Growth built into the price is above our model estimate.
The price assumes 107.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ICU — earnings in line
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, the Company issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities E…
Why it matters: Good safety results could boost trust and help future sales of QUELIMMUNE.
Supportive ifThe 28-day safety results show no problems related to the device.
Worry ifResults show many safety problems with the device or high death rates.
Why it matters: This would show strong growth momentum towards the $2 million target for 2026.
Supportive ifQ2 net product revenue reported at $0.75 million or higher.
Worry ifQ2 net product revenue reported below $0.5 million.
Why it matters: Meeting this revenue target would show progress toward the $2 million goal for 2026. It indicates growing demand for QUELIMMUNE therapy.
Supportive ifQ2 revenue is at or above $1 million. This shows strong sales growth.
Worry ifQ2 revenue is below $1 million. This suggests slower growth and market challenges.
Why it matters: These results could show that QUELIMMUNE works well. Good results may help it gain acceptance.
Supportive ifThe FDA got the 28-day safety results from the SAVE Registry. The outcomes are positive.
Worry ifResults show safety issues or bad outcomes. This could lead to regulatory problems.
Why it matters: This result could affect how investors feel and the company's image.
Worry ifA court ruling or settlement that favors the company.
Less concerning ifA ruling against the company that leads to financial penalties.
Why it matters: These codes will help with billing and may boost therapy use.
Supportive ifICD-10-PCS codes for SCD therapy are implemented on October 1, 2026.
Worry ifICD-10-PCS codes will not be used until after October 1, 2026.
Why it matters: Finishing enrollment is key to filing for FDA approval for adult AKI treatment. This could open a much larger market.
Supportive ifEnrollment reaches 339 patients by the end of 2026 as targeted.
Worry ifEnrollment does not grow much. It stays below 300 patients by year-end.
Why it matters: Steady revenue growth shows strong market acceptance. This helps future expansion plans.
Supportive ifQUELIMMUNE revenue grows by at least 70% year over year in Q3 2026.
Worry ifQUELIMMUNE revenue growth falls below 50% year over year in Q3 2026.
Why it matters: Getting regulatory approvals is key. It helps expand treatment options and market size.
Supportive ifSubmission of the modular PMA application to the FDA occurs by early 2027.
Worry ifNo progress on the PMA submission by early 2027.
Why it matters: Using these codes can make billing easier. It may boost therapy use in hospitals.
Supportive ifHospitals will use ICD-10-PCS codes for billing starting October 1, 2026.
Worry ifHospitals report issues or delays in using the new ICD-10-PCS codes for billing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$331 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $904 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,218 loss on $10,000 · 82.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.